1 min read
U.S. FDA issues two observations to Cipla arm InvaGen’s U.S. facility
thehindu.com
Tuesday, February 10, 2026
The observations followed a pre-approval inspection (PAI) by the regulator at InvaGen's manufacturing facility in Hauppauge, Long Island, New York
The observations followed a pre-approval inspection (PAI) by the regulator at InvaGen's manufacturing facility in Hauppauge, Long Island, New York
Read the full article
Continue reading on thehindu.com
More from thehindu.com
5 minutes ago
Honda net profit falls 42% on EV struggles and Trump tariffs
5 minutes ago
Support for Royal Family plummets after Epstein files revelations about Andrew
6 minutes ago
Deepak death case: Court further defers decision on Shimjitha’s bail plea
7 minutes ago